2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult, Animal Model
PAPER

3166 Efficacy and safety of complement inhibitors combined with cyclosporine a and thrombopoietin receptor agonist for paroxysmal nocturnal hemoglobinuria concurrent with aplastic anemia

Qilin Zhuang, Student at Peking Union Medical College, Yali Du, PhD2, Zepeng Li3, Yongxin Zhou4, Junling Zhuang, MD, PhD5, Leyu Wang6, Qi Wang, MD7, Ziwei Liu, MD8, Chen Yang9, Miao Chen, MD10, Bing Han11
1 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
2 Capital Medical University Affiliated Beijing Friendship Hospital, Beijing, China
3 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
4 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
5 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
6 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
7 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
8 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
9 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
10 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
11 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China

Objective: To investigate the efficacy and safety of complement inhibitors (CIs) combined with cyclosporine A (CsA) and thrombopoietin receptor agonists (TPO-RAs) in the treatment of patients with paroxysmal nocturnal hemoglobinuria concurrent with aplastic anemia (AA/PNH). Method: Data were retrospectively collected from 65 patients with AA/PNH at Peking Union Medical College Hospital between December 2022 and June 2025. All patients received regular CI therapy combined with full-dose CsA and TPO-RAs, with a follow-up of ≥ 6 months. Hemolysis, AA control, and adverse events were evaluated. Result: A total of 65 patients were included, with a median age at PNH diagnosis of 40 (18–79) years and a male proportion of 53.8% (35/65). 39 patients (60.0%) received eculizumab and 26 (40.0%) received iptacopan. All patients were treated with CsA combination of eltrombopag. The median treatment duration was 6 (6–36) months, and the median follow-up was 10 (6–36) months. At 1, 3, 6 months and at last follow-up, the overall response rates (ORR) were 84.6% (55/65), 89.2% (58/65), 93.8% (61/65), and 95.4% (62/65), respectively, whereas the complete response rates (CRR) were 0% (0/65), 12.3% (8/65), 18.5% (12/65), and 21.5% (14/65), respectively. At last follow-up, 89.2% (58/65) of patients achieved lactate dehydrogenase (LDH) < 1.5 × ULN and 56.9% (37/65) achieved LDH < 1.0 × ULN. Adverse events were mild and reversable. Propensity-matched subgroup analysis demonstrated that iptacopan was superior to eculizumab in improving LDH, hemoglobin(HGB), reticulocyte count, total bilirubin, and was associated with a lower incidence of breakthrough hemolysis (BTH) (all P < 0.05). Conclusion: The combination therapy of CI with CsA and TPO-RAs effectively ameliorates hemolysis and AA in patients with AA/PNH, demonstrating a favorable safety profile. Iptacopan exhibits superior hemolysis control compared with eculizumab in the short term.

Qilin Zhuang, Student at Peking Union Medical College: No relevant conflicts of interest to declare.